Methylphenidate Hydrochloride Tablets
Caraco Pharmaceutical Laboratories
Caraco Pharmaceutical Laboratories, a division of Sun Pharmaceutical Industries Limited, has released methylphenidate hydrochloride, a generic equivalent to Novartis’ Ritalin. It is indicated for the treatment of attention deficit disorder symptoms, including moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. It is contraindicated in patients with marked anxiety, tension, and agitation, in patients with motor tics or a family history or diagnosis of Tourette’s syndrome, and in patients with glaucoma.
Tablets: 5, 10, and 20 mg
For More Information: www.caraco.com
My Way LevonorgestreL Tablets, 1.5 Mg
Plan B (Teva Pharmaceuticals)
My Way levonorgestrel tablets, 1.5 mg, was launched by GAVIS Pharmaceuticals. My Way levonorgestrel tablets are a generic equivalent to Teva’s Plan B, and are indicated to prevent pregnancy after known or suspected contraceptive failure or unprotected intercourse. Tablets should be taken orally within 72 hours of unprotected intercourse or contraceptive failure. Tablets are more effective if taken earlier within the 72-hour window.
Tablets: 1.5 mg
For More Information: www.gavispharma.com
Diphenhydramine Hydrochloride Injection, USP
BD Rx Inc
BD has released Diphenhydramine Hydrochloride Injection, USP, to launch BD Simplist, its line of prefilled generic injectable medications. It is indicated for amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.
Injection: 50 mg/mL
For More Information: www.bd.com
Calcitriol Soft Gel Capsules
Heritage Pharmaceuticals Inc
Rocaltrol (Hoffmann-La Roche)
Heritage Pharmaceuticals Inc announces the availability of calcitriol soft gel capsules, an AB-rated generic equivalent to Hoffmann-La Roche’s synthetic vitamin D product Rocaltrol. It is indicated for the treatment of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure who are not yet on dialysis. It is also indicated for the management of hypocalcemia in patients who are undergoing dialysis.
Capsules: 0.25 and 0.5 mcg
For More Information: www.heritagepharma.com